Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Coiffier, Bertrand ^a   Pro, Barbara ^b   Prince, H Miles ^c   Foss, Francine ^d   Sokol, Lubomir ^e   Greenwood, Matthew ^f   Caballero, Dolores ^g   Morschhauser, Franck ^h   Wilhelm, Martin ⁱ   Pinter Brown, Lauren ^j   Padmanabhan Iyer, Swaminathan ^k   Shustov, Andrei ^l   Nielsen, Tina ^m   Nichols, Jean ⁿ   Wolfson, Julie ^o   Balser, Barbara ^o   Horwitz, Steven ^p  

^a HOSPICES CIVILS DE LYON   (France)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d YALE CANCER CENTER   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ KLINIKUM NÜRNBERG   (Germany)

^j UCLA MEDICAL CENTER   (United States)

^k HOUSTON METHODIST HOSPITAL   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

^m CELGENE CORPORATION   (United States)

ⁿ JNichols LLC   (United States)

^o Veristat   (United States)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Duration of response; Relapsed refractory peripheral T cell lymphoma; Romidepsin

Indexed keywords

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CELLULITIS; DEPSIPEPTIDES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS; VOMITING;

EID: 84892732599     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-11     Document Type: Article

References (33)

1. Peripheral T-cell lymphoma. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K, Blood 2011 117 25 6756 6767 10.1182/blood-2010-05-231548 21493798
2. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project, J Clin Oncol 2008 26 25 4124 4130 18626005
3. Management of peripheral T-cell non-Hodgkin's lymphoma. Horwitz SM, Curr Opin Oncol 2007 19 5 438 443 10.1097/CCO.0b013e3282ce6f8f 17762567 (Pubitemid 47356598)
4. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification. Ascani S, Zinzani PL, Gherlinzoni F, Sabattini E, Briskomatis A, de Vivo A, Piccioli M, Fraternali Orcioni G, Pieri F, Goldoni A, et al. Ann Oncol 1997 8 6 583 592 10.1023/A:1008200307625 9261528 (Pubitemid 27359419)
5. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Anderson JR, Armitage JO, Weisenburger DD, Ann Oncol 1998 9 7 717 720 10.1023/A:1008265532487 9739436 (Pubitemid 28394156)
6. Phenotypic analysis of peripheral T cell lymphoma among the Japanese. Nakamura S, Koshikawa T, Koike K, Kitoh K, Suzuki H, Oyama A, Motoori T, Kojima M, Ogura M, Kurita S, et al. Acta Pathol Jpn 1993 43 7-8 396 412 8372685 (Pubitemid 23225819)
7. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's Lymphoma Classification Project. Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Nathwani BN, Ullrich F, Müller-Hermelink HK, Ann Oncol 2002 13 1 140 149 10.1093/annonc/mdf033 11863096 (Pubitemid 34436738)
8. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphoma 2 2013
9. Foss FM, Carson KR, Pinter-Brown L, Horwitz SM, Rosen ST, Pro B, Federico M, Gisselbrecht C, Hsi ED, Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE): first detailed report of primary treatment [abstract 1614] Presented at: ASH Annual Meeting and Exposition 2012
10. Evens AM, Feldman T, Kroll A, Muffly LS, Winer E, Flowers C, Lansigan F, Nabhan C, Nastoupil L, Kim A, et al. Survival of newly diagnosed T-cell lymphoma (TCL) in the modern era: investigation of prognostic factors with critical examination of therapy in a multicenter US cohort [abstract 2728] Presented at: ASH Annual Meeting and Exposition, December 8-11 2012
11. Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas. Reimer P, Adv Hematol 2010 2010 320624 21253465
12. Hematopoietic SCT for peripheral T-cell lymphoma. Gutierrez A, Caballero MD, Perez-Manga G, Rodriguez J, Bone Marrow Transplant 2008 42 12 773 781 10.1038/bmt.2008.332 18936735
13. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Tan J, Cang S, Ma Y, Petrillo RL, Liu D, J Hematol Oncol 2010 3 5 10.1186/1756-8722-3-5 20132536
14. Anticancer activities of histone deacetylase inhibitors. Bolden JE, Peart MJ, Johnstone RW, Nat Rev Drug Discov 2006 5 9 769 784 10.1038/nrd2133 16955068 (Pubitemid 44348499)
15. Chemical phylogenetics of histone deacetylases. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R, Nat Chem Biol 2010 6 3 238 243 10.1038/nchembio.313 20139990
16. ISTODAX (romidepsin) [package insert] Summit, NJ: Celgene Corporation 2013
17. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, et al. J Clin Oncol 2012 30 6 631 636 10.1200/JCO.2011.37.4223 22271479
18. FOLOTYN (pralatrexate) [package insert], Westminster, CO: Allos Therapeutics, Inc 2009
19. Adcetris (brentuximab vedotin) [package insert], Bothell, WA: Seattle Genetics, Inc 2011
20. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, et al. J Clin Oncol 2011 29 9 1182 1189 10.1200/JCO.2010.29.9024 21245435
21. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, et al. J Clin Oncol 2012 30 18 2190 2196 10.1200/JCO.2011.38.0402 22614995
22. Pro B, Advani RH, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous JV, Ramchandren R, Fanale MA, Connors JM, et al. Long-term remissions observed in an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma [abstract 2745 Presented at: ASH Annual Meeting and Exposition, December 8-11 2012
23. Jacobsen ED, Advani RH, Oki Y, Sharman J, Horwitz SM, Forero-Torres A, O'Connor OA, Shustov AR, Siddiqi T, Grove LE, et al. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results [abstract 2746] Presented at: ASH Annual Meeting and Exposition, December 8-11 2012
24. Godfrey CJ, Cabell CH, Balser B, Wolfson J, Nichols J, Burris HA, Exposure-QTc response analysis of class 1 selective histone deacetylase inhibitor romidepsin Presented at: ASH Annual Meeting and Exposition, December 10-13 2011
25. Petrich AM, Helenowski I, Galamaga RW, Nabhan C, Trends in incidence and outcome in T-cell lymphoma since 1992: A SEER database analysis [abstract 4264] Presented at: ASH Annual Meeting and Exposition, December 8-11 2012
26. Improving outcomes for patients with large B-cell lymphoma. Flowers CR, Sinha R, Vose JM, CA Cancer J Clin 2010 60 393 408 21030533
27. Dupuis J, Casasnovas R, Ghesquieres H, Morschhauser F, Tilly H, Thieblemont C, Ribrag V, Coiffer B, A phase Ib trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the ro-CHOP study [abstract 1617] Presented at: ASH Annual Meeting and Exposition, December 8-11 2012
28. Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma http://www.clinicaltrials.gov/ct2/show/NCT01796002. Accessed March 4, 2013
29. Fanale MA, Shustov AR, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Kennedy DA, Horwitz SM, Combination chemotherapy and pralatrexate as first-line therapy in treating patients with non-Hodgkin lymphoma Presented at: ASH Annual Meeting and Exposition, December 8-11 2012
30. Combination chemotherapy and pralatrexate as first-line therapy in treating patients with non-Hodgkin lymphoma http://www.clinicaltrials.gov/ct2/ show/NCT01336933. Accessed December 21, 2012
31. Study of pralatrexate versus observation following CHOP-based chemotherapy in previously undiagnosed peripheral T-cell lymphoma patients http://www.clinicaltrials.gov/ct2/show/NCT01420679. Accessed March 4, 2013
32. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, NCI sponsored International Working Group, et al. J Clin Oncol 1999 17 4 1244 10561185
33. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE, Clin Cancer Res 2006 12 12 3762 3773 10.1158/1078-0432.CCR-05-2095 16778104 (Pubitemid 44000258)